Medo Gets FDA Clearance for AI-Powered Thyroid Ultrasound Tool

May 10, 2021

Medo has been granted FDA 510(k) clearance for its Medo-Thyroid software, an artificial intelligence (AI)-based tool that assists radiologists with thyroid ultrasounds.

The software performs rapid video analyses of each side of the thyroid gland and automatically selects optimal images for analysis, identifying any nodules that are present.

The AI system replaces the need for individually reviewing hundreds of images to locate and measure thyroid nodules.

View today's stories